Swiss National Bank
PVLA icon

Swiss National Bank’s Palvella Therapeutics PVLA Stock Holding History

Swiss National Bank’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Hold
19,400
– – ﹤0.01% 1721
2026
Q1 		$2.42M Buy
19,400
+5,200
+37% +$542K ﹤0.01% 1755
2025
Q4 		$1.49M Buy
+14,200
New +$1.21M ﹤0.01% 1999

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Swiss National Bank's PVLA Position: Q2 2026 in Review

Swiss National Bank held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 19,400 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1721.

Swiss National Bank first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Swiss National Bank held 19,400 shares of Palvella Therapeutics worth $2.96M as of Q2 2026.
  • Swiss National Bank left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1721 holding.
  • Swiss National Bank first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.